

=> d his

(FILE 'HOME' ENTERED AT 11:55:06 ON 07 MAY 2003)

FILE 'REGISTRY' ENTERED AT 11:55:16 ON 07 MAY 2003

L1 STRUCTURE UPLOADED

L2 3 S L1

L3 61 S L1 FULL


FILE 'CAPLUS' ENTERED AT 11:56:48 ON 07 MAY 2003

L4 42 S L3/USES

L5 31 S L4 AND (COSME? OR HAIR OR SKIN OR MASSACR?)

L6 1 S L5 NOT PY>=1999

L5 ANSWER 21 OF 31 CAPLUS COPYRIGHT 2003 ACS (Continued)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 22 OF 31 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1999:61162 CAPLUS
 DOCUMENT NUMBER: 130:110461
 TITLE: Preparation of an aqueous dispersion of lipid vesicles, comprised of cholesteryl carbanates, for use in cosmetic compositions
 INVENTOR(S): Philippe, Michel; Blaise, Christian; Simonnet, Jean-Thierry
 PATENT ASSIGNEE(S): L'Oreal, Fr.
 SOURCE: Eur. Pat. Appl., 15 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 890577	A1	19990113	EP 1998-401499	19980618
EP 890577	B1	20021106		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
FR 2765877	A1	19990115	FR 1997-8801	19970710
FR 2765877	B1	19990910		
US 6130213	A	20001010	US 1998-113565	19980710
			FR 1997-8801	A 19970710

PRIORITY APPLN. INFO.: MARPAT 130:110461
 OTHER SOURCE(S):
 AB A compn., comprised of an aq. dispersion of vesicles forming a lipid membrane, is characterized by the fact that aforementioned lipid membrane is comprised of at least a carbanate 1 (R1 = H, (un)satd. linear or branched hydroxylated C1-6-alkyl; R2 = (un)satd. linear or branched hydroxylated C3-6-alkyl; with provision that NR1R2 has two OH groups). The lipid vesicles are also comprised of amphiphiles, alkylsulfonic acid derivs. MOSO2CHR3CO2(CH2CH2O)2Me (R3 = C12-22-alkyl, Me(CH2)15, Me(CH2)17; M = alk. metal), and polyglycerol ethers R4O[CH2CH(CH2OH)O]nH [R4 = linear or branched C12-18-alkyl, R5CO, R6(OCHR7CH2), R6(OCH2CHR7); R5 = linear or branched C11-17-alkyl; R6 = R4, R5; R7 = R4; n = 2 - 6], R4O[CH2CH(OH)CH2O]nH or R4O[CH(CH2OH)CH2O]nH. Thus, N-(Cholesterylloxycarbonyl)-D-glucamine is prep'd. by reacting cholesterol chloroformate with D-glucamine in N,N-dimethylacetamide. Vesicles were prep'd. from N-(Cholesterylloxycarbonyl)-D-glucamine and monosodium glutamate and used in the formulation of a facial hydrating serum.
 IT 4358-16-1, Cholesterol phosphate
 RL: MOA (Modifier or additive use); USES (Uses)
 (prepn. of an aq. dispersion of lipid vesicles, comprised of cholesteryl carbanates, for use in cosmetics)
 RN 4358-16-1 CAPLUS
 CN Cholest-5-en-3-ol (3.beta.)-, dihydrogen phosphate (9CI) (CA INDEX NAME)
 Absolute stereochemistry.

L5 ANSWER 22 OF 31 CAPLUS COPYRIGHT 2003 ACS (Continued)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 23 OF 31 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1998:268334 CAPLUS
 DOCUMENT NUMBER: 129:8587
 TITLE: Method and compositions for disrupting the epithelial barrier function
 INVENTOR(S): Elias, Peter M.; Feingold, Kenneth R.; Holleran, Walter M.; Thornfeldt, Carl R.
 PATENT ASSIGNEE(S): Regents of the University of California, USA; Cellegy Pharmaceuticals, Inc.
 SOURCE: FCT Int. Appl., 62 pp.
 CODEN: P1XXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9817253	A1	19980430	WO 1997-US19343	19971022
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9749193	A1	19980515	AU 1997-49193	19971022
US 6190894	B1	20010220	US 1998-58401	19980409
			US 1996-733712	A 19961023
			US 1993-33811	B2 19930319
			US 1994-260559	B2 19940616
			WO 1997-US19343	W 19971022

PRIORITY APPLN. INFO.:
 AB Epithelial barrier function is disrupted in a host in need of topical administration of a physiol. active substance by applying to the epithelium a barrier-disrupting amt. of .storeq.1 agent selected from (1) inhibitors of synthesis of ceramides, acylceramides, glucosylceramides, sphingomyelins, fatty acids, or cholesterol; (2) degrad. enzymes for ceramides, acylceramides, glucosylceramides, or sphingomyelins; (3) inhibitors of degrad. of phospholipids, glycosphingolipids, glucosylceramides, acylceramides, or sphingomyelins; and (4) inhibitors and stimulators of metabolic enzymes of free fatty acids, ceramides, and cholesterol. Thus, a combination of 5-tetradecyloxy-2-furancarboxylic acid (an inhibitor of acetyl-CoA carboxylase which is the rate-limiting enzyme in free fatty acid synthesis) and .beta.-chloroalanine (an inhibitor of serine palmitoyltransferase, the rate-limiting enzyme in ceramide synthesis) increased delivery of lidocaine through mouse stratum corneum by 8-fold in vivo and increased transepidermal water loss. Thus, a combination of 5-tetradecyloxy-2-furancarboxylic acid (an inhibitor of acetyl-CoA carboxylase which is the rate-limiting enzyme in free fatty acid synthesis) and .beta.-chloroalanine (an inhibitor of serine palmitoyltransferase, the rate-limiting enzyme in ceramide synthesis) increased delivery of lidocaine through mouse stratum corneum by 8-fold in vivo and increased transepidermal water loss.
 IT 4358-16-1, Cholesterol phosphate
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (method and compns. for disrupting the epithelial barrier function)
 RN 4358-16-1 CAPLUS
 CN Cholest-5-en-3-ol (3.beta.)-, dihydrogen phosphate (9CI) (CA INDEX NAME)

L5 ANSWER 26 OF 31 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1997:440119 CAPLUS
 DOCUMENT NUMBER: 127:55642
 TITLE: Skin and hair cosmetic compositions comprising an aqueous dispersion of lipid vesicles encapsulating an acid-functional UV-filters
 INVENTOR(S): Simonnet, Jean-Thierry; Legret, Sylvie; Ribier, Alain
 PATENT ASSIGNEE(S): L'Oreal S. A., Fr.
 SOURCE: Eur. Pat. Appl., 21 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 775479	A1	19970528	EP 1996-402196	19961015
EP 775479	B1	19981028		
R: DE, ES, FR, GB, IT				
FR 2741263	A1	19970523	FR 1995-13876	19951122
FR 2741263	B1	19971226		
ES 2126371	T3	19990316	ES 1996-402196	19961015
US 5759526	A	19980602	US 1996-755314	19961122
PRIORITY APPLN. INFO.: MARPAT 127:55642			FR 1995-13876	19951122

OTHER SOURCE(S):
 AB Skin and hair cosmetic compns. comprising an aq. dispersion of lipid vesicles encapsulating an acid-functional UV-filters are claimed. The lipid vesicles are formed from an amphiphilic non-ionic lipid, an amphiphilic ionic lipid, a sand. hydrocarbon having iodine index .ltoreq.10, and a totally neutralize amphiphilic ionic lipid. A cream contained Tween 61 3.8, N,N-dimethyl-N-(hydroxy-2-ethyl)ammonium dodecanoyl-5-salicylate 3.8, cholesterol 3.8, benzene-1,4-di(3-methylidenecampho-10-sulfonic) 5.00, triethanolamine 1.0, tocopherol acetate 0.5, glycerin 5.0, and water q.s. 50%.

IT 4358-16-1D, Cholesterol phosphate, alkali metal salts
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (skin and hair cosmetic compns. comprising aq. dispersion of lipid vesicles encapsulating acid-functional UV-filters)
 RN 4358-16-1 CAPLUS
 CN Cholest-5-en-3-ol (3.beta.)-, dihydrogen phosphate (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 26 OF 31 CAPLUS COPYRIGHT 2003 ACS (Continued)



L5 ANSWER 27 OF 31 CAPLUS COPYRIGHT 2003 ACS


ACCESSION NUMBER: 1996:634951 CAPLUS
 DOCUMENT NUMBER: 125:256771
 TITLE: Transparent nanoemulsion based on amphiphilic nonionic lipids and use in cosmetics
 INVENTOR(S): Ribier, Alain; Simonnet, Jean-Thierry; Legret, Sylvie
 PATENT ASSIGNEE(S): Oreal S. A., Fr.
 SOURCE: Eur. Pat. Appl., 8 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 728460	A1	19960828	EP 1996-400210	19960130
EP 728460	B1	19970827		
R: DE, ES, GB, IT				
FR 2730932	A1	19960830	FR 1995-2268	19950227
FR 2730932	B1	19970404		
ES 2110854	T3	19980216	ES 1996-400210	19960130
JP 08245371	A2	19960924	JP 1996-38272	19960226
JP 2962678	B2	19991012		
CN 1138456	A	19961225	CN 1996-106000	19960226
CN 1104890	B	20030409		
US 5753241	A	19980519	US 1996-607353	19960226
BR 9600628	A	19971230	BR 1996-628	19960227
PRIORITY APPLN. INFO.: FR 1995-2268 A 19950227				

AB A transparent oil-in-water emulsion with av. globule size of .ltoreq.100 nm comprising amphiphilic nonionic lipids for use in cosmetics is disclosed. A cosmetic moisturizer contained .alpha.-butylglucoside cocoate 4.5, Acylglutamate HS21 (N-stearoyl L-glutamic acid disodium salt) 0.5, jojoba oil 5, avocado oil 5, volatile silicone 6, stearylheptanoate-stearylcaprylate 2, vitamin E acetate 1, ethanol 15, glycerin 6, sodium hyaluronate 0.10, and water q.s. 100%. The transparent emulsion had globules of 52 nm and transparency of 5%.

IT 4358-16-1D, Cholesterol phosphate, alk. salts
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (transparent nanoemulsion based on amphiphilic nonionic lipids and use in cosmetics)
 RN 4358-16-1 CAPLUS
 CN Cholest-5-en-3-ol (3.beta.)-, dihydrogen phosphate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 27 OF 31 CAPLUS COPYRIGHT 2003 ACS (Continued)

L5 ANSWER 28 OF 31 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1996:631950 CAPLUS
 DOCUMENT NUMBER: 125:256745
 TITLE: Cosmetic composition based on lipid vesicles containing acids and its use in topical application
 INVENTOR(S): Terren, Nadia; Perrin, Martine; Michelet, Jacques
 PATENT ASSIGNEE(S): Oreal S. A., Fr.
 SOURCE: Eur. Pat. Appl., 20 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 728459	A1	19960828	EP 1996-400163	19960123
EP 728459	B1	19970326		
R: DE, ES, FR, GB, IT				
FR 2730928	A1	19960830	FR 1995-2136	19950223
FR 2730928	B1	19970404		
ES 2102919	T3	19970801	ES 1996-400163	19960123
CN 1136430	A	19961127	CN 1996-106076	19960222
JP 08245338	A2	19960924	JP 1996-36860	19960223
BR 9600613	A	19971230	BR 1996-613	19960223
US 5804216	A	19980908	US 1996-605921	19960223

PRIORITY APPLN. INFO.: FR 1995-2136 A 19950223

OTHER SOURCE(S): MARPAT 125:256745

AB Cosmetic compns. based on lipid vesicles contg. acids, pH 4.0 to 5.5, are disclosed. A cosmetic foundation contained Generalol 122E5 1.6, hydrogenated lecithin 2.4, Me p-hydroxybenzoate 0.2, guanosine 0.01, glycerin 3, propylene glycol 3, palm oil 6.5, apricot kernel oil 9.5, Bu p-hydroxybenzoate 0.09, Pr p-hydroxybenzoate 0.1, volatile silicone 7158, vitamin E acetate 0.5, Givaudan 1, yellow iron oxide 0.89, brown iron oxide 0.49, black iron oxide 0.11, titanium oxide 5.51, preservative 0.3, Sepigel 305 2, mixt. of .alpha.-hydroxyacids 1, crosslinked starch 3, and water q.s. 100 g.

IT 4358-16-1D, Cholesterol phosphate, alk. salts
 RI: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)


(cosmetic compn. based on lipid vesicles contg. acids and its use in topical application)

RN 4358-16-1 CAPLUS

CN Cholest-5-en-3-ol (3.beta.)-, dihydrogen phosphate (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 28 OF 31 CAPLUS COPYRIGHT 2003 ACS (Continued)



L5 ANSWER 29 OF 31 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1996:311454 CAPLUS
 DOCUMENT NUMBER: 124:325030
 TITLE: Dermatologic or cosmetic composition comprising an oil in water emulsion based on oily globules coated with a lamellar liquid crystal coating
 INVENTOR(S): Ribier, Alain; Simonnet, Jean-Thierry; Michelet, Jacques
 PATENT ASSIGNEE(S): Oreal S. A., Fr.
 SOURCE: Eur. Pat. Appl., 13 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 705593	A1	19960410	EP 1995-402156	19950926
EP 705593	B1	19961023		
R: AT, BE, CH, DE, ES, FR, GB, IT, LI, NL, SE				
FR 2725369	A1	19960412	FR 1994-12005	19941007
FR 2725369	B1	19970103		
AT 144409	E	19961115	AT 1995-402156	19950926
ES 2096505	T3	19970301	ES 1995-402156	19950926
BR 9504781	A	19961015	BR 1995-4781	19951005
CA 2160071	AA	19960408	CA 1995-2160071	19951006
JP 08127526	A2	19960521	JP 1995-259655	19951006
JP 2650881	B2	19970910		
RU 2128504	C1	19990410	RU 1995-117053	19951006
US 5925364	A	19990720	US 1995-540165	19951006
PL 182151	B1	20011130	PL 1995-310848	19951006

PRIORITY APPLN. INFO.: FR 1994-12005 A 19941007

OTHER SOURCE(S): MARPAT 124:325030

AB The title cosmetic compns. are disclosed. A skin moisturizer lotion contained sucrose distearate 1.5, Tween 61 1, Acylglutamate HS21 0.75, stearyl heptanoate 3, vaseline 1, volatile silicone oil 2, jojoba oil 2, vitamin E acetate 0.5, Q2-1403 Fluid 2, propylparaben 0.1, fragrance 0.3, glycerin 5, methylparaben 0.3, propylene glycol 3, Carbopol 940 0.3, triethanolamine 0.1, and water q.s. 100%.

IT 4358-16-1D, Cholesterol phosphate, alkali salts
 RI: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)


(dermatol. or cosmetic compn. comprising oil in water emulsion based on oily globules coated with lamellar liq. crystal coating)

RN 4358-16-1 CAPLUS

CN Cholest-5-en-3-ol (3.beta.)-, dihydrogen phosphate (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 29 OF 31 CAPLUS COPYRIGHT 2003 ACS (Continued)



L5 ANSWER 30 OF 31 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1995:216799 CAPLUS
 DOCUMENT NUMBER: 122:1102
 TITLE: Method and compositions for disrupting the epithelial barrier function
 INVENTOR(S): Elias, Peter M.; Thornfeldt, Carl R.; Grayson, Stephen
 PATENT ASSIGNEE(S): Cellegy Pharmaceuticals, Inc., USA; Regents of the University of California
 SOURCE: PCT Int. Appl., 64 pp.
 CODEN: P1XXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9421230	A1	19940929	WO 1994-US3030	19940321
W: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KG, KP, KR, KZ, LK, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, EJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
IL 109037	A1	19990126	IL 1994-109037	19940318
AU 9465894	A1	19941011	AU 1994-65894	19940321
EP 764017	A1	19970326	EP 1994-913927	19940321
R: BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, PT, SE				
US 5723114	A	19980303	US 1996-639212	19960426
US 5885565	A	19990323	US 1996-638302	19960426
US 6010691	A	20000104	US 1996-639191	19960426
PRIORITY APPLN. INFO.:			US 1993-33807	19930319
			WO 1994-US3030	19940321
			US 1994-261343	19940616

AB This invention relates generally to a novel method for enhancing penetration of physiol. active substances for cutaneous or transdermal delivery through epithelium which comprises the stratum corneum/epidermis and keratinizing mucous membranes. More specifically, it relates to a method and compn. for disrupting the epithelial barrier function in a host by applying to the epithelium a barrier-disrupting amt. of at least one agent selected from the group consisting of an inhibitor of ceramide synthesis, an inhibitor of acylceramide synthesis, an inhibitor of glucosylceramide synthesis, an inhibitor of sphingomyelin synthesis, an inhibitor of fatty acid synthesis, an inhibitor of cholesterol synthesis, a degrdn. enzyme of ceramides, acylceramide, glucosylceramides, sphingomyelin, an inhibitor of phospholipid, glycosphingolipid, including glucosylceramide, acylceramide or sphingomyelin degrdn., and both inhibitors and stimulators of metabolic enzymes of free fatty acids, ceramide, and cholesterol.

IT 4358-16-1, Cholesterol phosphate
 RI: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (method and compns. for disrupting epithelial barrier function for skin drug transport)

RN 4358-16-1 CAPLUS
 CN Cholest-5-en-3-ol (3.beta.)-, dihydrogen phosphate (9CI) (CA INDEX NAME)

L5 ANSWER 30 OF 31 CAPLUS COPYRIGHT 2003 ACS (Continued)
 Absolute stereochemistry.



L5 ANSWER 31 OF 31 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1994:586800 CAPLUS
 DOCUMENT NUMBER: 121:186800
 TITLE: Stabilization of vesicles of amphiphilic lipids in topical emulsions
 INVENTOR(S): Ribier, Alain; Simonnet, Jean-Thierry
 PATENT ASSIGNEE(S): Oreal S. A., Fr.
 SOURCE: Eur. Pat. Appl., 27 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 611207	A1	19940817	EP 1994-400271	19940209
EP 611207	B1	20010620		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, NL, PT, SE				
FR 2701396	A1	19940819	FR 1993-1612	19930212
FR 2701396	B1	19950421		
AT 202277	E	20010715	AT 1994-400271	19940209
ES 2157964	T3	20010901	ES 1994-400271	19940209
CA 2115504	AA	19940813	CA 1994-2115504	19940211
US 6051250	A	20000418	US 1994-195025	19940214
PRIORITY APPLN. INFO.:			FR 1993-1612	A 19930212

OTHER SOURCE(S): MARPAT 121:186800
 AB Lipid vesicles in topical emulsions are stabilized with stabilizing agents such as glycerol alginate or propylene glycol alginate. A lotion contained glyceryl stearate 2.8, stearyl alc. 0.75, vaseline 12, lanolin 0.5, almond oil 2, Pr parahydroxybenzoate 0.5, Me parahydroxybenzoate 0.2, glycerin 5, Germal 115 0.05, Carbopol 941 0.1, triethanolamine 0.13, soya lecithin 2.5, water 73.91, and Manucol ester E/F (propylene glycol alginate) 0.01 g.

IT 4358-16-1, Cholesterol phosphate
 RI: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (stabilization of vesicles of amphiphilic lipids in topical emulsions)

RN 4358-16-1 CAPLUS
 CN Cholest-5-en-3-ol (3.beta.)-, dihydrogen phosphate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 4358-16-1 CAPLUS
 CN Cholest-5-en-3-ol (3.beta.)-, dihydrogen phosphate (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 31 OF 31 CAPLUS COPYRIGHT 2003 ACS (Continued)

